Union européenne - croate - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplazme dojki - antineoplastična sredstva - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Union européenne - croate - EMA (European Medicines Agency)

laboratorios hipra, s.a. - Эймери acervulina, procijediti 003, Эймери maksimu, procijediti 013, Эймери митис, procijediti 006, Эймери ргаесох, procijediti 007, Эймери tenella, procijediti 004 - Živjeti parazitski cjepiva, imunomodulatori za ptice - piletina - za aktivna imunizacija pilića od 1 dana starosti za smanjenje poraza crijeva ооцисты i izlaz, povezan s кокцидиоза uzrokovane Эймери acervulina, Эймери maksimu, Эймери митис, Эймери ргаесох i Эймери tenella i smanjiti kliničke manifestacije (proljev), povezana je s Эймери acervulina, Эймери maksima i Эймери tenella.

Union européenne - croate - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - parvo svinja, soj 27a, virusni protein 2 - imunološke za suidae - svinje - za aktivne imunizacije popravak svinje i krmače u dobi od 5 mjeseci do zaštitu potomstva od infekcije трансплацентарный uzrokovana parvo svinja.

Union européenne - croate - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojki - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Union européenne - croate - EMA (European Medicines Agency)

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - imunološke za suidae - svinje - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.

Union européenne - croate - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - svinje - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Union européenne - croate - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - cjepiva protiv gripe - profilakcija influence uzrokovana virusom a (h1n1v) 2009. focetria mora se koristiti u skladu sa službenim vodstvom.

Union européenne - croate - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - antigeni virusa influence (hemaglutinin i neuraminidaza) soja a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - cjepiva - aktivna imunizacija protiv h5n1 podtipa virusa gripe a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Union européenne - croate - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - cjepivo protiv pandemijskog gripa (h5n1) (split Вирион, инактивированный, адъювантом) - influenza, human; immunization; disease outbreaks - cjepiva - profilakcija gripe u službeno prijavljenoj pandemijskoj situaciji. pandemije gripe cjepivo bi trebao biti korišten u skladu sa službenim vodstvom.

Union européenne - croate - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split virusa influence, inaktiviran, koji sadrži antigen: a / vietnam / 1194/2004 (h5n1) kao soj koji se koristio (nibrg-14) - influenza, human; immunization; disease outbreaks - cjepiva - profilakcija gripe u službeno prijavljenoj pandemijskoj situaciji. cjepivo protiv influence pandemije treba koristiti u skladu s službenim smjernicama.